{"groups":[{"description":"Participants with juvenile pilocytic astrocytomas or optic pathway gliomas receiving PEGINTRON based on their weight (1 mcg/kg/dose) once a week, for up to two years","id":"FG000","title":"PEGINTRON"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were enrolled at Children's Healthcare of Atlanta, in Atlanta, Georgia. Enrollment began November 2014 and all follow up was complete by November 11, 2020."}